Podcast
Play an AI-generated podcast conversation about this lesson
Questions and Answers
Administration of cis-retinoic acid is a type of immunotherapy for neuroblastoma.
Administration of cis-retinoic acid is a type of immunotherapy for neuroblastoma.
False (B)
Immunotherapy is used to eliminate residual disease after chemotherapy for neuroblastoma.
Immunotherapy is used to eliminate residual disease after chemotherapy for neuroblastoma.
True (A)
Stage IV neuroblastoma has a low rate of spontaneous regression.
Stage IV neuroblastoma has a low rate of spontaneous regression.
False (B)
Neuroblastoma has a 5-year survival rate of 50% in children.
Neuroblastoma has a 5-year survival rate of 50% in children.
Signup and view all the answers
Recurrent disease is rare in children with neuroblastoma.
Recurrent disease is rare in children with neuroblastoma.
Signup and view all the answers
The prognosis is worse in children diagnosed before 1 year of age.
The prognosis is worse in children diagnosed before 1 year of age.
Signup and view all the answers
There are no known risk factors associated with osteosarcoma development.
There are no known risk factors associated with osteosarcoma development.
Signup and view all the answers
Retinoblastoma is not linked to an elevated risk of osteosarcoma development.
Retinoblastoma is not linked to an elevated risk of osteosarcoma development.
Signup and view all the answers
Fibrous dysplasia is not a risk factor for osteosarcoma.
Fibrous dysplasia is not a risk factor for osteosarcoma.
Signup and view all the answers
Hereditary multiple exostoses is not a risk factor for osteosarcoma.
Hereditary multiple exostoses is not a risk factor for osteosarcoma.
Signup and view all the answers
